Aurora Cannabis Inc. (ACB) reports its financial results for the first quarter, shares rise
Aurora Cannabis first-quarter revenue beat estimates, sending its shares up more than 30 in the pre-market trading Monday
Staff or Guest writer for The Dog of Wall Street.
2020-11-09 10:41

Aurora Cannabis Inc. (ACB) shares skyrocketed more than 30 percent in the pre-market trading Monday after the company announced its financial results for the fiscal first quarter. The Edmonton, Canada-based cannabis producer posted a loss of C$107.2 million for the three-month period ending September 30, as compared to a loss of C$1.85 billion in the prior quarter.

Revenue for the quarter came in at C$67.8 million, slightly higher than C$67.5 million in the fourth quarter. Analysts surveyed by FactSet had revenue forecast of C$63.6 million. The company did not offer a comparison with the comparable period last. 

If we analyze the segment-wise sales, the company generated revenue of C$34.3 million from its consumer cannabis segment in Q1, down 3 percent from the prior quarter. Comparatively, revenue from medical cannabis jumped 4 percent to $33.5 million. Moreover, it sold 16,139 kg of weed in the quarter, down from 16,746 kg in the fourth quarter. 

Dried cannabis was sold at an average price of C$3.72, higher than C$3.60 in the prior quarter. 

Speaking on the results, Aurora Cannabis CEO Miguel Martin said in a statement "our Q1 2021 results are transitional but do highlight successes across a number of diverse profit pools. We remain the leader by revenue in the high-margin Canadian medical market, our international medical business experienced more than 40% net revenue growth this quarter, and our CBD brand Reliva is #1 ranked by Nielsen in the U.S. CBD sector."

Aurora Cannabis (ACB) shares are currently trading around $12 on heavy volume of 47 million as compared to average volume of 17.76 million. ACB shares gained significant value over the past week on news related to expanded use of cannabis in several states of America. The company’s share price is expected to rise further if use of marijuana is legalized in the U.S.

Disclaimer: I have no positions in any of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article. All information should be independently verified and should not be relied upon for purposes of transacting securities or other investments. See terms for more info.

Published On
2020-11-09 10:41

About the Author
Staff or Guest writer for The Dog of Wall Street.

Analyst Ratings
Target Price $9.98
# of Analysts 3
Last updated 2021-09-20

Canopy Growth Leads the Way
Canopy’s stock is already up over 18% since the start of the year, and has recovered nicely since the sudden bear market in March of 2020 when it hit single digit prices.
By Mike Sakuraba | 9 months ago

The Future of Cannabis Stocks in 2021
When is the right time to buy stock in the cannabis market? The time is now!
By Staff | 9 months ago

Can Aurora Cannabis Ever Return to Glory?
While Aurora is still standing on its own two feet, the Canadian company will need to produce some positive earnings news or another rough quarter could lie ahead.
By Mike Sakuraba | 1 year ago

2 Stocks You Need to Upgrade Now
Let’s take a look at a couple companies that recently took another step in their growth stories.
By Mike Sakuraba | 1 day ago

Tesla's Forecast for 2022
The electric vehicle sector has been busy as of late, but not much in terms of news from Tesla.
By Mike Sakuraba | 5 days ago

Better Investment: Pfizer or Moderna
This week I take a look at two stalwarts in the pharmaceutical industry, and the effect they have had on investors in the race for a COVID-19 vaccine.
By Mike Sakuraba | 1 week ago